Viet Le, DMSc, PA-C, discusses early data from the Target-D trial and how this might influence the way he interprets the findings from other vitamin D supplementation studies.
Results of the ARTESIA trial suggest apixaban lowered stroke risk by 37% in subclinical atrial fibrillation versus aspirin, but increased major bleeding risk.
Full data from the SELECT trial offer insight into the 20% relative risk reduction associated with use of semaglutide 2.4 mg in patients with overweight or obesity and preexisting cardiovascular disease at AHA 2023.
The MINT trial, which included 3504 patients with acute MI and anemia, shows a trend favoring liberal transfusion, indicating a potential for improved outcomes.